On May 9, 2014, Amicus Therapeutics, Inc. (NASDAQ:FOLD) updated its Investor Presentation for the Migalastat Monotherapy Program (the “Presentation”). The Company’s Chief Financial Officer, William D. Baird III and the Company’s Chief Operating Officer, Bradley L. Campbell, will present some or all of this Presentation to various investors in the coming months. A copy of the presentation materials is attached hereto as Exhibit 99.1. Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock performance was 7.32% in last session and finished the day at $2.20. Traded volume was 317,548.00million shares in the last session and the average volume of the stock remained 469.22K shares. The beta of the stock remained 1.15. Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider ownership is 2.80%.

Relypsa Inc. (NASDAQ:RLYP) has announced that it has entered into a manufacturing contract with DSM Fine Chemicals. The multi-year commercial manufacturing and supply contract will be for the production of the active pharmaceutical ingredient, or API, of patiromer, which will be used in the development of hyperkalemia treatment. Relypsa Inc (NASDAQ:RLYP) rose 16.45 percent to $25.41 Thursday on volume of 335,099.00million shares. The intra-day range of the stock was $22.05 to $25.63. Relypsa Inc (NASDAQ:RLYP) has a market capitalization of $860.01million.

Receptos Inc (NASDAQ:RCPT) Director S. Edward Torres sold 424,068 shares of the company’s stock on the open market in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $25.26, for a total transaction of $10,711,957.68. Receptos Inc (NASDAQ:RCPT)’s stock on May 22, 2014 reported a increase of 10.64% to the closing price of $28.28. Its fifty two weeks range is $13.00 -$55.00. The total market capitalization recorded $626.95million. The overall volume in the last trading session was 388,049.00million shares. In its share capital, RCPT has 22.17million outstanding shares.

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced upcoming presentations of clinical data for TG-1101, the Company’s next generation, glycoengineered anti-CD20 monoclonal antibody and for TGR-1202, the Company’s novel, once-daily PI3k delta inhibitor, at the 19th Congress of the European Hematology Association (EHA), being held June 12 – 15, 2014 in Milan, Italy. On Thursday, shares of TG Therapeutics, Inc. (NASDAQ:TGTX) advanced 13.89% to close the day at $5.33. Company return on investment (ROI) is -56.00% and its monthly performance is recorded as 3.29%. TG Therapeutics, Inc. (NASDAQ:TGTX) quarterly revenue growth is -4.65%.

Shares of Chimerix Inc (NASDAQ:CMRX) , a clinical-stage biopharmaceutical company focused on developing oral antiviral products, surged as much as 15% after it announced the pricing of a secondary share offering. According to company’s press release, which came out after the closing bell last night, it priced 7.3 million shares at $14.22 per share, the same as yesterday’s closing price. Chimerix Inc (NASDAQ:CMRX) stock performance was 5.43% in last session and finished the day at $17.08. Traded volume was 409,924.00million shares in the last session and the average volume of the stock remained 371.30K shares. Chimerix Inc (NASDAQ:CMRX) insider ownership is 0.30%.